Basaloid follicular hamartoma

Summary

Basaloid follicular hamartoma (MONDO:0021977) is a disease. A subtype of hamartoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	basaloid follicular hamartoma
Mondo ID	MONDO:0021977
ICD-11	648125144
NCIT	C4749
SNOMED CT	254705003
UMLS	C0474964
MedGen	96887
Is cancer (heuristic)	no

Also known as: basal cell nevus with comedones · basaloid follicular hamartoma

Disease family

This is a subtype of hamartoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hamartoma › basaloid follicular hamartoma

Related subtypes (12): chondroid hamartoma, gastrointestinal hamartoma, linear nevus sebaceous syndrome, linear and whorled nevoid hypermelanosis, congenital epulis, congenital smooth muscle hamartoma, hamartoma of skin appendage, hamartoma of lung, angiomyomatous hamartoma, giant mammary hamartoma, mesenchymal hamartoma, odontoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.